Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fukuda Denshi Co., Ltd. (6960.T)
JPY11,370.00
+40.00 (+0.35%)
JP JPX Healthcare Medical - Devices
Address
2-35-8 Hongo 113-8420
Tokyo, JP
Tokyo, JP
CEO
Kotaro Fukuda
Website
fukuda.com
IPO
2000-01-04
ISIN JP3806000000
Description
Fukuda Denshi Co., Ltd. manufactures and supplies medical devices to both Japanese and international clients. Their offerings span a range of products, including resting electrocardiography equipment, data management software, and stress test apparatus. Additionally, they provide comprehensive patient monitoring systems, such as central and bedside monitors, transmitters, and central viewer workstations, as well as vascular screening solutions. The company, headquartered in Tokyo, Japan, was established in 1939.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY11,370.00
+40.00 (+0.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
51.0K
Beta
0.60
Float Shares
8.14M
Free Float %
30.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.46% | +6.36% | +5.82% | +15.57% | +50.79% | +36.53% | +62.15% | +124.73% | +145.12% | +270.47% | +1,039.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11,370.00
DCF (Unlevered)
13,580.01
+19.4%
DCF (Levered)
15,066.16
+32.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.07
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+0.5% Q1'26: +3.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+5.9% Q1'26: +19.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.1% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+19.1% ★ Q1'26: +25.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+14.6% ★ Q1'26: +22.4% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-4.6% ★ Q1'26: -5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.09× ★ Q1'26: 0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
108.27B
est: 106.00B (+2.1%)
|
117.22B
est: 113.00B (+3.7%)
|
121.75B
est: 121.55B (+0.2%)
|
128.88B
est: 132.00B (-2.4%)
|
129.78B
est: 130.00B (-0.2%)
|
133.39B
est: 130.00B (+2.6%)
|
146.76B
est: 146.76B (+0.0%)
|
132.10B
est: 132.10B (+0.0%)
|
134.65B
est: 132.00B (+2.0%)
|
140.32B
est: 130.00B (+7.9%)
|
139.01B
est: 141.24B (-1.6%)
|
138.85B
138.70B – 139.00B
-1.7% YoY
|
142.30B
141.81B – 142.79B
+2.5% YoY
|
147.00B
146.00B – 148.00B
+3.3% YoY
|
151.50B
150.98B – 152.02B
+3.1% YoY
|
156.40B
155.86B – 156.94B
+3.2% YoY
|
| EBITDA |
16.64B
est: 26.27B (-36.7%)
|
17.24B
est: 28.00B (-38.4%)
|
19.13B
est: 30.12B (-36.5%)
|
19.79B
est: 32.71B (-39.5%)
|
20.50B
est: 32.21B (-36.4%)
|
21.30B
est: 32.21B (-33.9%)
|
28.17B
est: 36.36B (-22.5%)
|
31.73B
est: 32.73B (-3.1%)
|
33.46B
est: 32.71B (+2.3%)
|
36.23B
est: 43.43B (-16.6%)
|
36.42B
est: 44.59B (-18.3%)
|
43.83B
43.79B – 43.88B
-1.7% YoY
|
44.92B
44.77B – 45.08B
+2.5% YoY
|
46.41B
46.09B – 46.72B
+3.3% YoY
|
47.83B
47.66B – 47.99B
+3.1% YoY
|
49.38B
49.20B – 49.55B
+3.2% YoY
|
| EBIT |
10.30B
est: 19.06B (-45.9%)
|
10.65B
est: 20.32B (-47.6%)
|
12.06B
est: 21.85B (-44.8%)
|
12.34B
est: 23.73B (-48.0%)
|
12.65B
est: 23.37B (-45.9%)
|
13.28B
est: 23.37B (-43.2%)
|
19.81B
est: 26.39B (-24.9%)
|
22.71B
est: 23.75B (-4.4%)
|
24.10B
est: 23.73B (+1.5%)
|
26.51B
est: 31.48B (-15.8%)
|
25.88B
est: 29.96B (-13.6%)
|
29.45B
29.42B – 29.48B
-1.7% YoY
|
30.18B
30.08B – 30.29B
+2.5% YoY
|
31.18B
30.97B – 31.39B
+3.3% YoY
|
32.13B
32.02B – 32.24B
+3.1% YoY
|
33.17B
33.06B – 33.29B
+3.2% YoY
|
| Net Income |
7.12B
est: 7.29B (-2.3%)
|
7.37B
est: 6.38B (+15.5%)
|
8.78B
est: 8.46B (+3.7%)
|
9.32B
est: 8.46B (+10.1%)
|
9.58B
est: 8.71B (+9.9%)
|
9.61B
est: 8.71B (+10.3%)
|
14.72B
est: 14.03B (+4.9%)
|
16.22B
est: 15.46B (+4.9%)
|
17.28B
est: 14.96B (+15.5%)
|
18.69B
est: 13.44B (+39.1%)
|
18.61B
est: 16.37B (+13.6%)
|
18.17B
17.86B – 18.47B
+11.0% YoY
|
18.18B
18.10B – 18.26B
+0.1% YoY
|
18.80B
18.32B – 19.97B
+3.4% YoY
|
19.80B
18.93B – 21.40B
+5.3% YoY
|
21.23B
21.14B – 21.33B
+7.2% YoY
|
| SGA |
32.44B
est: 32.32B (+0.4%)
|
32.86B
est: 34.45B (-4.6%)
|
33.99B
est: 37.06B (-8.3%)
|
35.33B
est: 40.24B (-12.2%)
|
35.59B
est: 39.63B (-10.2%)
|
36.78B
est: 39.63B (-7.2%)
|
37.52B
est: 44.74B (-16.1%)
|
41.42B
est: 40.27B (+2.9%)
|
40.71B
est: 40.24B (+1.2%)
|
41.48B
est: 38.20B (+8.6%)
|
41.98B
est: 44.37B (-5.4%)
|
43.62B
43.57B – 43.67B
-1.7% YoY
|
44.71B
44.55B – 44.86B
+2.5% YoY
|
46.18B
45.87B – 46.50B
+3.3% YoY
|
47.60B
47.43B – 47.76B
+3.1% YoY
|
49.14B
48.97B – 49.31B
+3.2% YoY
|
| EPS |
256.04
est: 252.71 (+1.3%)
|
252.75
est: 221.25 (+14.2%)
|
287.76
est: 293.55 (-2.0%)
|
306.24
est: 293.53 (+4.3%)
|
314.68
est: 302.30 (+4.1%)
|
316.52
est: 302.25 (+4.7%)
|
486.67
est: 486.65 (+0.0%)
|
536.21
est: 536.20 (+0.0%)
|
571.23
est: 519.00 (+10.1%)
|
622.44
est: 466.10 (+33.5%)
|
645.40
est: 595.40 (+8.4%)
|
660.65
649.54 – 671.76
+11.0% YoY
|
661.10
658.12 – 664.08
+0.1% YoY
|
696.30
666.30 – 726.30
+5.3% YoY
|
733.35
688.50 – 778.20
+5.3% YoY
|
772.20
768.72 – 775.68
+5.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.00B
OE per share TTM
67.50
Owner's Yield
0.74%
Maintenance CapEx ratio
16.35%
Maint CapEx / Avg PPE
32.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
7.73M
Shares Outstanding
27.02M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kotaro Fukuda | Chairman & Chief Executive Officer | 430M | male |
| Daijiro Shirai | Chief Operating Officer, President & Director | 204M | male |
| Haruo Ogawa | MD, GM of Technology & Quality Assurance Division and Director | — | male |
| Kazuo Genchi | MD, General Manager of Sales Headquarters & Director | — | male |
| Naoki Hisano | MD & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6960.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
